Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Operating Leases: 2023-2025

Historic Operating Leases for Zenas BioPharma (ZBIO) over the last 1 years, with Sep 2025 value amounting to $180,000.

  • Zenas BioPharma's Operating Leases was N/A to $180,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $180,000, marking a year-over-year change of. This contributed to the annual value of $218,000 for FY2024, which is 15.18% down from last year.
  • As of Q3 2025, Zenas BioPharma's Operating Leases stood at $180,000, which was down 16.28% from $215,000 recorded in Q2 2025.
  • Over the past 5 years, Zenas BioPharma's Operating Leases peaked at $317,000 during Q1 2025, and registered a low of $180,000 during Q3 2025.
  • In the last 3 years, Zenas BioPharma's Operating Leases had a median value of $218,000 in 2024 and averaged $237,400.
  • Data for Zenas BioPharma's Operating Leases shows a maximum YoY fell of 15.18% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Zenas BioPharma's Operating Leases stood at $257,000 in 2023, then dropped by 15.18% to $218,000 in 2024, then reached $180,000 in 2025.
  • Its Operating Leases was $180,000 in Q3 2025, compared to $215,000 in Q2 2025 and $317,000 in Q1 2025.